Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Business https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ JPMorgan’s earnings for the first quarter of past forecasts; Dimon sees “extremely strong, multi-year growth”

JPMorgan’s earnings for the first quarter of past forecasts; Dimon sees “extremely strong, multi-year growth”


Raymond James predicts over 60% rally for these 2 shares

Repelled with incredible force, the S&P 500 has gained 50% in the last 12 months, and the index is already ashamed of its 52-week peak. This impressive charge came when investors gave up on COVID-19’s devastating impact on the economy. Moving forward, Raymond strategist James Tavis McCourt believes we are looking at a long period of higher interest rates, higher taxes and abundant economic growth. “[It] it seems very likely that the puck will be in a very strong economy, low unemployment, with higher long-term rates and probably higher tax rates in the next 6-1

2 months. EPS bias is likely to be higher this year as reopens occur, as any EPS shortfall is likely to be due to supply or inflation problems rather than a lack of demand, “McCourt said. economic indicators paint a rosy picture, and McCourt believes that some of the potential negatives (the political preference of the Biden administration, for example, to higher tax rates, for example) are already at a price. JFK: “The rising tide is lifting all the boats.” Clearly, the rest of the street agrees, each winning a consensus rating of “Strong Purchase.” Pioneer Natural Resources (PXD) We’ll start in Texas, in the oil section of The Perm Basin, where Pioneer Natural Resources is the main owner of land and a company for exploration and production of hydrocarbons. Pioneer has more than 1.27 billion barrels of oil equivalent in its proven reserves; that number includes 357 million barrels added through a survey in 2020. Operations on its farms yielded Q4 earnings of $ 1.07 per share, exceeding consensus estimates of $ 0.69 per share. For the full year 2020, Pioneer reported a net loss of $ 1.21 per share; this number was strongly affected by interruptions due to the COVID pandemic crisis. in addition, in 2020, operating cash flow reached $ 2.1 billion and free cash flow of $ 689 million. The company uses this free cash flow to fund a $ 521 million return on equity program. Much of the return on capital is made through the company’s dividend, which in the last declaration was increased by one penny to 56 cents per ordinary share paid per quarter. The company has built its stable position by acquiring, in effect this month, a competitor, DoublePoint Energy. The acquisition costs Pioneer the equivalent of $ 6.4 billion – divided by 21.2 million shares from ordinary shares of PXD, $ 1 billion in cash and the rest, $ 900 million, in debt and debt. Covering the PXD for Raymond James, analyst John Freeman wrote of the acquisition: “We expect significant performance improvements from longer sidelines on acquired space in addition to typical G&A and interest rate interactions. The acquisition of 97,000 net acres increases PXD’s Perm lease to> 1 million net acres. The analyst added: “With the acquisition of DoublePoint Energy, Pioneer has further established itself as Permian Basin’s leading clean game E&P with the highest level of area and balance. The company’s ability to generate significant FCFs must be more than sufficient to fulfills its intentions to return a significant return to shareholders … ”According to his comments, the analyst estimates PXD as a strong buy, with a target price of $ 245 to indicate a one-year high of 67%. here) Overall, the word on the street is predominantly upward for this oil stock, as TipRanks analytics show PXD as a strong buy.Of the 24 analysts surveyed in the last 3 months, 19 are bullish and 5 are left aside. 29%, the consensus share price is $ 190.57. (See PXD stock analysis for TipRanks) NexImmune (NEXI) By shifting gears, we will move from the energy industry to bio the technological field where NexImmune is an early-stage biotechnology company in oncology developing T-cell immunotherapies. In short, the company is exploring ways to boost a patient’s own immune system to fight cancer. The company has a development pipeline involving two leading drug candidates, NEXI-001 and NEXI-002, which are in phase 1/2 of clinical trials as a treatment for acute myeloid leukemia (AML) that has recurred after allogeneic stem cell transplantation or multiple myeloma refractory> 3 previous lines of therapy, respectively. The company has four more programs at different stages of early preclinical development. In the fourth quarter of last year, NexImmune announced that the first patient had been dosed in a Phase 1/2 study for NEXI-002. Also in 4Q20, initial results in the first 5 patients treated with NEXI-001 showed “early signs” that the drug candidate was safe and elicited a strong immune response. NexImmune expects additional data on these trials in 2Q21 and a more complete set of results by the end of this year. In the process of raising capital, NexImmune in February 2021 conducted an initial public offering (IPO) on the US stock exchange NASDAQ. The company issued 7.441 million shares at a price of $ 17 per share. The sale, before expenses, raised $ 126.5 million for the company. NexImmune’s move to NASDAQ prompted Raymond analyst James Stephen Seedhouse to begin covering the stock. The analyst rates NEXI at superiority (ie Buying), along with a price tag of $ 30, suggesting 64% up next year. (To view the Seedhouse record, click here) “Individually, we view NexImmune programs as high risk / high reward (ie, low PoS but high unregulated revenue potential), plus we generally believe that the platform is likely to gave a successful therapeutic approach with guidance from an experienced management team, ”said Seedhouse. The analyst added: “NexImmune’s AIM ACT technology involves cell therapy called tumor infiltrating lymphocytes (TIL) and [rival] Iovance has shown promising data in a phase 2 study of TIL lifileucel in metastatic melanoma. Unlike the more targeted NEXI-001, lifileucel consists of a highly variable combination of T-cell clonotypes. We believe that Iovance’s market capitalization north of $ 4B is an ambitious goal for NexImmune. “This company has only had time to get three analyst reviews since it started trading in US markets – but all three have to buy, making analysts’ consensus on the stock a strong buy. The stock is currently priced at 18.28 dollars and have an average target of 33.33 dollars, which suggests an increase of ~ 82% this year. (See the analysis of shares of NEXI on TipRanks) To find good ideas for stocks trading at attractive prices, visit “Best stocks TipRanks, a recently launched tool that brings together all TipRanks property statistics. Disclaimer: The views expressed in this article are for the analysts presented only. The content is for informational purposes only. it is important to do your own analysis before making any investment.

Source link